Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript February 21, 2024 5:00 PM ET

Company Participants

Nate Harrill - VP of IR

Kevin Conroy - Chairman and CEO

Jeff Elliott - CFO

Everett Cunningham - CCO

Brian Baranick - GM, Precision Oncology

Conference Call Participants

Brandon Couillard - Jefferies

Catherine Schulte - Baird

Doug Schenkel - Wolfe Research

Dan Brennan - Cowen

Vijay Kumar - Evercore ISI

Dan Arias - Stifel

Andrew Brackmann - William Blair

Matt Sykes - Goldman Sachs

Patrick Donnelly - Citi

Jack Meehan - Nephron Research

Puneet Souda - Leerink Partners

Andrew Cooper - Raymond James

Dan Leonard - UBS

Subbu Nambi - Guggenheim

Mark Massaro - BTIG

Operator

Good afternoon, and welcome to the Exact Sciences Fourth Quarter 2023 Earnings Call. Please be advised that this call is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. I would now like to turn the conference over to Mr. Nate Harrill, Vice President of Investor Relations, you may begin your conference.

Nate Harrill

Thanks, Jeanne. Thank you for joining us for Exact Sciences fourth quarter 2023 conference call. On the call today are Kevin Conroy, the Company's Chairman and CEO, and Jeff Elliott, our Chief Financial Officer. Everett Cunningham, our Chief Commercial Officer, and Brian Baranick, our General Manager of Precision Oncology will also be available for questions.

Exact Sciences issued a news release earlier this afternoon detailing our fourth-quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website.

I'll now turn the call over to Kevin.

Kevin Conroy

Thanks, Nate. 2023 was another record-breaking year for Exact Sciences and our fourth quarter results set the tone for an impactful year ahead. A special thanks to our team for testing a record number of people during the quarter with our established brands Cologuard, Oncotype DX, and PreventionGenetics. We've built an unrivaled platform that will allow us to achieve our purpose to help eradicate cancer.